Can repetitive transcranial magnetic stimulation be used as an adjunctive treatment for Tourette syndrome that has not responded to first‑line behavioral therapy and standard pharmacologic agents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

TMS for Treatment-Refractory Tourette Syndrome

Repetitive transcranial magnetic stimulation (rTMS) can be considered as an adjunctive treatment option for severe, treatment-refractory Tourette syndrome, though the evidence remains limited and less robust than for deep brain stimulation.

Current Evidence Base

The most recent systematic review and meta-analysis 1 from 2025 provides important context: when analyzing only randomized controlled trials, rTMS showed a statistically insignificant decrease in tic severity (YGTSS scores: MD = -5.01, P = 0.090). However, when combining RCTs with non-randomized trials, rTMS demonstrated significant improvement (MD = -11.6, P < 0.001). This discrepancy highlights the weakness of the current evidence base.

Key Considerations for Clinical Decision-Making

When to Consider rTMS:

  • Severe tics causing physical discomfort, pain, or injury
  • Failed first-line treatments: inadequate response to behavioral therapy (CBIT) and at least two standard pharmacological agents (alpha-2 agonists, dopamine antagonists)
  • Patient preference for less invasive intervention before considering deep brain stimulation
  • Comorbid OCD: rTMS showed more consistent benefit for obsessive-compulsive symptoms (MD = -6.6, P = 0.010) 1

Protocol Specifications:

The most studied approach targets the supplementary motor area (SMA) bilaterally with:

  • Low-frequency stimulation (1 Hz)
  • 20 sessions over 4-6 weeks
  • fMRI-guided targeting when available 2

Critical Limitations

The evidence quality is problematic 3. Most studies are small case series or open-label trials. Only three controlled studies exist, and publication bias likely favors positive results 4. The 2022 systematic review 3 emphasizes that while results "tentatively suggest" benefit, the lack of large-scale sham-controlled studies severely limits confidence in these findings.

Comparative Effectiveness

Deep brain stimulation demonstrates superior efficacy for treatment-refractory TS. DBS showed significant improvement in RCTs (YGTSS: MD = -14.71, P < 0.001) 1 with approximately 97% of published cases showing substantial tic improvement [@1-7@]. However, DBS is invasive, requiring neurosurgery with inherent risks.

Practical Algorithm

  1. Confirm treatment resistance: Document failed trials of behavioral therapy plus ≥2 pharmacological agents
  2. Assess severity: Tics must cause significant functional impairment, not just be present
  3. Screen for contraindications: Seizure history, metallic implants, pregnancy
  4. Trial rTMS before DBS: Given its non-invasive nature, despite weaker evidence
  5. Monitor response: Use validated scales (YGTSS) at baseline, mid-treatment, and post-treatment
  6. Consider DBS referral: If rTMS fails after adequate trial (20+ sessions)

Important Caveats

  • Durability unknown: Most studies lack long-term follow-up beyond 3 months 5
  • Optimal parameters uncertain: Target location, frequency, and session number remain under investigation 3
  • Not FDA-approved for Tourette syndrome
  • Insurance coverage may be limited or unavailable
  • Comorbidities matter: Patients with TS-OCD may respond better than those with pure TS 5

The evidence suggests rTMS may provide modest benefit as a bridge therapy between standard treatments and invasive neurosurgery, but clinicians should set realistic expectations given the limited and inconsistent evidence base.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.